Exploratory Pharmacokinetics of Geniposide in Rat Model of Cerebral Ischemia Orally Administered with or without Baicalin and/or Berberine

Table 2

Pharmacokinetic differences of oral administration of geniposide, geniposide : baicalin, geniposide : berberine, and geniposide : baicalin : berberine to MCAO rats.

Parameters	Geniposide	Geniposide : baicalin	Geniposide : berberine	Geniposide : baicalin : berberine
AUC(0--𝑡) (mg/L*h)	14.59±4.24	49.59±2.68^∗∗	16.04±4.61	26.88±13.83
AUC(0--∞) (mg/L*h)	23.63±13.02	59.00±10.59^∗∗	21.32±9.36	30.61±14.56
AUMC(0--𝑡)	136.73±54.16	435.39±48.12^∗∗	135.39±39.93	203.81±116.58
AUMC(0--∞)	235.03±196.14	589.97±73.48	188.91±55.26	297.80±137.63
MRT(0--𝑡) (h)	9.15±1.38	8.77±0.72	8.47±1.24	7.42±0.97^∗
MRT(0--∞) (h)	22.52±17.38	13.13±4.83	15.81±6.91	11.76±4.95
VRT(0--𝑡) (h^2)	49.40±7.29	43.48±10.59	53.26±20.10	41.71±15.44
VRT(0--∞) (h^2)	770.40±1189.48	177.17±164.06	316.07±248.52	188.61±178.69
𝑡1/2𝑧 (h)	15.11±12.73	8.47±3.45	10.41±6.17	8.42±4.45
𝑇max ( h)	0.96±0.53	0.55±0.19	0.88±0.65	0.60±0.39
CL𝑧/𝐹 (L/h/kg)	8.05±4.76	2.47±0.37	7.55±2.52	5.38±2.05
V𝑧/𝐹 (L/kg)	119.31±41.06	28.72±6.09^∗∗	97.81±49.63	66.23±43.19
𝐶max (mg/L)	1.48±0.19	5.68±1.19^∗∗	2.99±0.87^∗∗	3.99±1.08^∗∗

Values are given as means ± SD of 6 rats.
∗P < 0.05, compared with pure geniposide group.
∗∗P < 0.01, compared with pure geniposide group.